
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. has demonstrated positive financial trends, highlighted by sequential growth in adjusted operating margins across its segments, with Life Sciences increasing by 20 basis points to 13.1%, and Bioprocessing rising by 120 basis points to 26.6%, attributed to fixed cost leverage and ongoing cost transformation initiatives. The company's organic revenue for the fourth quarter reached $1.69 billion, showing a 1.0% growth, bolstered by a strong performance in the Bioprocessing segment and consistent resilience in Life Sciences driven by contract wins and customer relationship expansions. Looking ahead, Avantor is poised for enhanced margins and revenue growth, with forecasts indicating organic revenue growth of 1.0% to 3.0% for FY25, supported by favorable market conditions and the anticipated benefits from pricing and volume increases.
Bears say
Avantor Inc. is facing potential revenue declines in its small biotech sub-segment due to a slowdown in purchasing patterns, which may negatively impact overall financial performance. Additionally, the company's financial metrics indicate mixed results across various end markets and product segments, with organic revenue growth in biopharma & healthcare being offset by declines in education & government and advanced tech & applied materials. Compounding these challenges, prolonged inventory destocking at customer levels poses further risks to guidance and revenue estimates, highlighting a precarious outlook for Avantor's stock.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares